Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995184 | 1.00 | CETP (0.78) | CETP | |
| SCHEMBL992842 | 0.94 | CETP (0.75) | CETP | |
| SCHEMBL992962 | 0.94 | CETP (0.75) | CETP | |
| SCHEMBL1895914 | 0.92 | CETP (0.67) | CETP | |
| SCHEMBL993142 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL992847 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL992704 | 0.90 | CETP (0.64) | CETP | |
| SCHEMBL992659 | 0.90 | CETP (0.64) | CETP | |
| SCHEMBL1900194 | 0.90 | CETP (0.75) | CETP | |
| SCHEMBL993565 | 0.89 | CETP (0.63) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070282009-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC | 2007-12-06 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1608628-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2004082638-A2 | HISTONE DEACETYLASE INHIBITORS | SYRRX, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-6723753-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-07-03 | — | — | US | claimed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | claimed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | claimed |
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-19 | — | — | US | claimed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | claimed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | claimed |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-29 | — | — | US | claimed |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-22 | — | — | US | claimed |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-08 | — | — | US | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2305217-B1 | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | BEND RES INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8703196-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8389011-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389006-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120295988-A1 | Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers | BEND RESEARCH, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120277315-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | BEND RESEARCH, INC. | 2012-11-01 | — | — | US | disclosed |
| US-8236328-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8197848-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8173142-B2 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8147872-B2 | Pharmaceutical compositions of drugs and neutralized acidic polymers | Bend Reseach, Inc. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| EP-2305217-A1 | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | Bend Research, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7897175-B2 | Cholesteryl ester transfer protein (CETP) such as torcetrapib; 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase); two drugs are separate from each other; improved chemical stability of the HMG-CoA reductase inhibitor | BEND RESEARCH, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7887840-B2 | Bioavailability of low- solubility drugs | BEND RESEARCH, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-1404302-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ADSORBATES OF AMORPHOUS DRUG | PFIZER PROD INC (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1399190-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | BEND RES INC (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-1961419-B1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090011024-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | PFIZER INC. | 2009-01-08 | — | — | US | disclosed |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER INC | 2008-11-27 | — | — | US | disclosed |
| EP-1961419-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | Pfizer Products Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1581210-B1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PROD INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070282009-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC | 2007-12-06 | — | — | US | disclosed |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER PRODUCTS INC. | 2007-06-28 | — | — | US | disclosed |
| US-7235259-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1401503-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PROD INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| US-20060216351-A1 | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers | PFIZER INC. | 2006-09-28 | — | — | US | disclosed |
| US-7071210-B2 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060128751-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC | 2006-06-15 | — | — | US | disclosed |
| EP-1653926-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060014788-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-20060003011-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PFIZER INC | 2006-01-05 | — | — | US | disclosed |
| US-6962931-B2 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1581210-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578448-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1578415-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1519754-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTASE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1519752-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050038007-A1 | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2005011634-A1 | DOSAGE FORMS PROVIDING CONTROLLED RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1474144-A1 | CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR | Pfizer Products Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040197398-A1 | Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor | PFIZER INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| EP-1453544-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| WO-2004056395-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056358-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056359-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056396-A1 | DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| EP-1404302-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404300-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1399190-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | Pfizer Products Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040053842-A1 | Methods of treatment with CETP inhibitors and antihypertensive agents | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004004777-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004778-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTABLE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003000235-A9 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030198674-A1 | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | BEND RESEARCH INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030186952-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030170309-A1 | Pharmaceutical compositions containing polymer and drug assemblies | BABCOCK WALTER C (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003063868-A1 | CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | LONZA BEND INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (43 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20040197398-A1 | Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | CETP 1/4885 |
| US-20030170309-A1 | Pharmaceutical compositions containing polymer and drug assemblies | PRNP, PUF60, ABCB1 | CETP 315/4885 |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | ABCB1, ABCG2, CYP3A7 | CETP 63/4885 |
| US-20040053842-A1 | Methods of treatment with CETP inhibitors and antihypertensive agents | CETP, APOB, MTTP | CETP 1/4885 |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | CETP 534/4885 |
| US-20120277315-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | ABCG2, ALB, SLCO1A2 | CETP 162/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885 |
| US-20050038007-A1 | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | CETP, HMGCR, DBI | CETP 1/4885 |
| US-20030186952-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | ABCG2, ALB, SLCO1A2 | CETP 162/4885 |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | ABCC1, ABCG2, PGD | CETP 485/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885 |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | CETP 1/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885 |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | CETP 1/4885 |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20060216351-A1 | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers | ABCB11, ABCG2, LIPA | CETP 229/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | CETP 1/4885 |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | CETP 1/4885 |
| US-20090011024-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | CETP 534/4885 |
| US-20030198674-A1 | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | CETP, DBI, NPC1L1 | CETP 1/4885 |
| US-20060014788-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885 |
| US-20120295988-A1 | Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers | ABCG2, ABCB1, MATR3 | CETP 534/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885 |
| US-20060003011-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | CETP 1214/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CETP 1/4885 |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CETP 227/4885 |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | CETP, HMGCR, CHLSN | CETP 1/4885 |
| US-20070282009-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885 |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | ABCG2, ALB, SLCO1A2 | CETP 162/4885 |
| US-20060128751-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.